REPORT HIGHLIGHT
Pseudomonas aeruginosa infection treatment Market size was valued at USD 1,607.8 million in 2022, expanding at a CAGR of 6.8% from 2023 to 2030.
Pseudomonas aeruginosa infections are generally treated with antibiotics. However, due to the bacterium's ability to develop resistance, selecting appropriate antibiotics can be challenging. Pseudomonas aeruginosa has been known to develop resistance to various antibiotics, an including those commonly used to treat infections. However, certain antibiotics, such as polymyxins can still be effective against multidrug-resistant strains. Additionally, newer antibiotics and alternative therapies, such as bacteriophages and monoclonal antibodies, are being explored as potential treatment options for multidrug-resistant Pseudomonas aeruginosa infections.
Pseudomonas aeruginosa infection treatment Market- Market Dynamics
Increasing consumer awareness about Pseudomonas aeruginosa infection treatment to propel market demand
Increasing consumer awareness about Pseudomonas aeruginosa infection treatment can certainly have a positive impact on market demand for related products and services. increasing consumer awareness can also adoptive interest and investment in research and development efforts to combat Pseudomonas aeruginosa infections. Consumer awareness can also lead to increased demand for supportive care and patient engagement services. The demand for Pseudomonas aeruginosa infection treatment is driven by several factors, including the increasing prevalence of Pseudomonas aeruginosa infections, rising antibiotic resistance, and others. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections identified that Pseudomonas aeruginosa (PA) is responsible for 10-15% of nosocomial infections worldwide.
Pseudomonas aeruginosa infection treatment Market- Key Insights
- As per the analysis shared by our research analyst, the global Pseudomonas aeruginosa infection treatment market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
- The Pseudomonas aeruginosa infection treatment industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on treatment segmentation, Combination Therapy was predicted to show maximum market share in the year 2022
- Based on drug type segmentation, Cephalosporin was the leading type in 2022
- Based on Route of Administration segmentation, Intravenous was the leading type in 2022
- Based on distribution channels segmentation, Hospitals was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Pseudomonas aeruginosa infection treatment Market- Segmentation Analysis:
The Global Pseudomonas aeruginosa infection treatment Market is segmented on the basis of treatment type, drug type, route of administration, distribution channel, and Region.
The market is divided into three categories based on treatment type: Monotherapy and Combination Therapy. Combination Therapy dominates the market. It is particularly in demand for the treatment of severe infections or infections caused by multidrug-resistant strains of Pseudomonas aeruginosa.
The market is divided into four categories based on drug type: Cephalosporin, Aminoglycoside, Carbapenem, Monobactam, and Others. Cephalosporin propels market growth, due to It can be effective against certain strains of Pseudomonas aeruginosa, it's worth mentioning that this bacterium is known to be inherently resistant to many cephalosporin's, especially the first-generation cephalosporin's.
The market is divided into three categories based on the Route of Administration: Nasal, Oral, and Intravenous. Intravenous dominates the market and is likely to maintain its dominance during the forecast period, due to the availability of drugs for the Intravenous route, and high occurrence in dosing.
The market is divided into three categories based on distribution channels: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospitals dominate the market and are likely to maintain their dominance during the forecast period. It plays a crucial role in diagnosing, treating, and preventing Pseudomonas aeruginosa infections. They have the resources, expertise, and patient population that necessitate effective treatment strategies for managing these infections.
Pseudomonas aeruginosa infection treatment Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the Pseudomonas aeruginosa infection treatment Market, due to a rise in the number of Pseudomonas aeruginosa infections. The elderly population may be particularly disposed to pseudomonad infection as a result of increased co-morbidities, the presence of invasive devices such as urinary catheters and feeding tubes, and polypharmacy that includes antibacterial, and immune compromise related to age. According to the center for disease control and Prevention, in 2017, multidrug-resistant Pseudomonas aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States. However, Asia Pacific and Europe are also expected to offer substantial growth opportunities for the Pseudomonas aeruginosa infection treatment market during the forecast period.
Pseudomonas aeruginosa infection treatment Market- Competitive Landscape:
The treatment market for Pseudomonas aeruginosa infections is competitive, with several pharmaceutical companies offering antibiotics and other therapeutic options to combat these infections. pharmaceutical companies involved in the development and marketing of antibiotics for Pseudomonas aeruginosa infections through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Additionally, the ability to develop new antibiotics or combination therapies to address emerging drug resistance in Pseudomonas aeruginosa is crucial for maintaining competitiveness in this market. For example, in 2023, SPR-206 is under clinical development by Pfizer and is currently in Phase I for Pseudomonas aeruginosa Infections. According to Global Data, Phase I drugs for Pseudomonas aeruginosa Infections has a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Recent Developments:
Allergan plc recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.
Key features of the study:
- This proposed research study on Pseudomonas aeruginosa infection treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Pseudomonas aeruginosa infection treatment market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Pseudomonas aeruginosa infection treatment market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Pseudomonas aeruginosa infection treatment market
- Impact of COVID-19 on Pseudomonas aeruginosa infection treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Pseudomonas aeruginosa infection treatment market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Pseudomonas aeruginosa infection treatment market, we have also included competitive landscape and key innovator analysis for the Pseudomonas aeruginosa infection treatment market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Pseudomonas aeruginosa infection treatment market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Pseudomonas aeruginosa infection treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET KEY PLAYERS
- Allergan
- Pfizer Inc.
- Merck & Co. Inc.
- AstraZeneca PLC
- Novartis AG
- Lupin Pharmaceuticals Inc.
- EnBiotix Inc
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Co.
- Humanigen Inc
- Other
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE
- Monotherapy
- Combination Therapy
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE
- Cephalosporin
- Aminoglycoside
- Carbapenem
- Monobactam
- Others
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA